Status:
UNKNOWN
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Lead Sponsor:
Prince of Songkla University
Conditions:
Critical Illness
Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed in critically ill patients with severe infections. These patients show several pathophysiological changes ...
Eligibility Criteria
Inclusion
- age \>18 years
- severely ill patient who admitted to medical or surgical intensive care unit who require a treatment with meropenem or imipenem antibiotic
Exclusion
- severe renal impairment and require renal replacement therapy
- APACHE II score \>30
- History of hypersensitivity to carbapenems
- Pregnancy or breast-feeding female
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT03858387
Start Date
September 1 2018
End Date
December 31 2021
Last Update
May 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Prince of Songkla University, Thailand
Hat Yai, Changwat Songkhla, Thailand, 90110